Andrea Atkinson, Arianne Albert, Elisabeth McClymont, Janice Andrade, Lori Beach, Shelly Bolotin, Isabelle Boucoiran, Jared Bullard, Carmen Charlton, Joan Crane, Shelley Dougan, Jean-Claude Forest, Greg J German, Yves Giguère, Gabriel Girouard, Catherine Hankins, Mel Krajden, Amanda Lang, Paul Levett, Jessica Minion, Cory Neudorf, Vanessa Poliquin, Jason L Robinson, Heather Scott, Derek R Stein, Vanessa Tran, George Zahariadis, Hong Y Zhou, Deborah Money
{"title":"加拿大使用产前血清样本进行SARS-CoV-2血清学调查:回顾性血清阳性率研究","authors":"Andrea Atkinson, Arianne Albert, Elisabeth McClymont, Janice Andrade, Lori Beach, Shelly Bolotin, Isabelle Boucoiran, Jared Bullard, Carmen Charlton, Joan Crane, Shelley Dougan, Jean-Claude Forest, Greg J German, Yves Giguère, Gabriel Girouard, Catherine Hankins, Mel Krajden, Amanda Lang, Paul Levett, Jessica Minion, Cory Neudorf, Vanessa Poliquin, Jason L Robinson, Heather Scott, Derek R Stein, Vanessa Tran, George Zahariadis, Hong Y Zhou, Deborah Money","doi":"10.9778/cmajo.20220045","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Insufficient data on the rate and distribution of SARS-CoV-2 infection in Canada has presented a substantial challenge to the public health response to the COVID-19 pandemic. Our objective was to assess SARS-CoV-2 seroprevalence in a representative sample of pregnant people throughout Canada, across multiple time points over 2 years of the pandemic, to describe the seroprevalence and show the ability of this process to provide prevalence estimates.</p><p><strong>Methods: </strong>This Canadian retrospective serological surveillance study used existing serological prenatal samples across 10 provinces over multiple time periods: Feb. 3-21, 2020; Aug. 24-Sept. 11, 2020; Nov. 16-Dec. 4, 2020; Nov. 15-Dec. 3, 2021; and results from the province of British Columbia during a period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant, from Nov. 15, 2021, to June 11, 2022. Age and postal code administrative data allowed for comparison with concurrent polymerase chain reactivity (PCR)-positive results collected by Statistics Canada and the Canadian Surveillance of COVID-19 in Pregnancy (CANCOVID-Preg) project.</p><p><strong>Results: </strong>Seropositivity in antenatal serum as early as February 2020 indicates SARS-CoV-2 transmission before the World Health Organization's declaration of the pandemic. Seroprevalence in our sample of pregnant people was 1.84 to 8.90 times higher than the recorded concurrent PCR-positive prevalence recorded among females aged 20-49 years in November-December 2020. Overall seropositivity in our sample of pregnant people was low at the end of 2020, increasing to 15% in 1 province by the end of 2021. Seroprevalence among pregnant people in BC during the Omicron period increased from 5.8% to 43% from November 2021 to June 2022.</p><p><strong>Interpretation: </strong>These results indicate widespread vulnerability to SARS-CoV-2 infection before vaccine availability in Canada. During the time periods sampled, public health tracking systems were under-reporting infections, and seroprevalence results during the Omicron period indicate extensive community spread of SARS-CoV-2 infection.</p>","PeriodicalId":10432,"journal":{"name":"CMAJ open","volume":"11 2","pages":"E305-E313"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/b4/cmajo.20220045.PMC10079308.pdf","citationCount":"1","resultStr":"{\"title\":\"Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study.\",\"authors\":\"Andrea Atkinson, Arianne Albert, Elisabeth McClymont, Janice Andrade, Lori Beach, Shelly Bolotin, Isabelle Boucoiran, Jared Bullard, Carmen Charlton, Joan Crane, Shelley Dougan, Jean-Claude Forest, Greg J German, Yves Giguère, Gabriel Girouard, Catherine Hankins, Mel Krajden, Amanda Lang, Paul Levett, Jessica Minion, Cory Neudorf, Vanessa Poliquin, Jason L Robinson, Heather Scott, Derek R Stein, Vanessa Tran, George Zahariadis, Hong Y Zhou, Deborah Money\",\"doi\":\"10.9778/cmajo.20220045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Insufficient data on the rate and distribution of SARS-CoV-2 infection in Canada has presented a substantial challenge to the public health response to the COVID-19 pandemic. Our objective was to assess SARS-CoV-2 seroprevalence in a representative sample of pregnant people throughout Canada, across multiple time points over 2 years of the pandemic, to describe the seroprevalence and show the ability of this process to provide prevalence estimates.</p><p><strong>Methods: </strong>This Canadian retrospective serological surveillance study used existing serological prenatal samples across 10 provinces over multiple time periods: Feb. 3-21, 2020; Aug. 24-Sept. 11, 2020; Nov. 16-Dec. 4, 2020; Nov. 15-Dec. 3, 2021; and results from the province of British Columbia during a period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant, from Nov. 15, 2021, to June 11, 2022. Age and postal code administrative data allowed for comparison with concurrent polymerase chain reactivity (PCR)-positive results collected by Statistics Canada and the Canadian Surveillance of COVID-19 in Pregnancy (CANCOVID-Preg) project.</p><p><strong>Results: </strong>Seropositivity in antenatal serum as early as February 2020 indicates SARS-CoV-2 transmission before the World Health Organization's declaration of the pandemic. Seroprevalence in our sample of pregnant people was 1.84 to 8.90 times higher than the recorded concurrent PCR-positive prevalence recorded among females aged 20-49 years in November-December 2020. Overall seropositivity in our sample of pregnant people was low at the end of 2020, increasing to 15% in 1 province by the end of 2021. Seroprevalence among pregnant people in BC during the Omicron period increased from 5.8% to 43% from November 2021 to June 2022.</p><p><strong>Interpretation: </strong>These results indicate widespread vulnerability to SARS-CoV-2 infection before vaccine availability in Canada. During the time periods sampled, public health tracking systems were under-reporting infections, and seroprevalence results during the Omicron period indicate extensive community spread of SARS-CoV-2 infection.</p>\",\"PeriodicalId\":10432,\"journal\":{\"name\":\"CMAJ open\",\"volume\":\"11 2\",\"pages\":\"E305-E313\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/b4/cmajo.20220045.PMC10079308.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CMAJ open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9778/cmajo.20220045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CMAJ open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9778/cmajo.20220045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study.
Background: Insufficient data on the rate and distribution of SARS-CoV-2 infection in Canada has presented a substantial challenge to the public health response to the COVID-19 pandemic. Our objective was to assess SARS-CoV-2 seroprevalence in a representative sample of pregnant people throughout Canada, across multiple time points over 2 years of the pandemic, to describe the seroprevalence and show the ability of this process to provide prevalence estimates.
Methods: This Canadian retrospective serological surveillance study used existing serological prenatal samples across 10 provinces over multiple time periods: Feb. 3-21, 2020; Aug. 24-Sept. 11, 2020; Nov. 16-Dec. 4, 2020; Nov. 15-Dec. 3, 2021; and results from the province of British Columbia during a period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant, from Nov. 15, 2021, to June 11, 2022. Age and postal code administrative data allowed for comparison with concurrent polymerase chain reactivity (PCR)-positive results collected by Statistics Canada and the Canadian Surveillance of COVID-19 in Pregnancy (CANCOVID-Preg) project.
Results: Seropositivity in antenatal serum as early as February 2020 indicates SARS-CoV-2 transmission before the World Health Organization's declaration of the pandemic. Seroprevalence in our sample of pregnant people was 1.84 to 8.90 times higher than the recorded concurrent PCR-positive prevalence recorded among females aged 20-49 years in November-December 2020. Overall seropositivity in our sample of pregnant people was low at the end of 2020, increasing to 15% in 1 province by the end of 2021. Seroprevalence among pregnant people in BC during the Omicron period increased from 5.8% to 43% from November 2021 to June 2022.
Interpretation: These results indicate widespread vulnerability to SARS-CoV-2 infection before vaccine availability in Canada. During the time periods sampled, public health tracking systems were under-reporting infections, and seroprevalence results during the Omicron period indicate extensive community spread of SARS-CoV-2 infection.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
